Kashi Clinical Laboratories (KCL), a market leader in transplantation immunodiagnostic lab testing, has recently expanded it’s collaboration with Thermo Fisher Scientific and Transcriptome Sciences to deliver Molecular Microscope™ Diagnostic System for Lung. This new laboratory developed test for post-transplant biopsy assessment is designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment.
“Accelerating clinical decision-making through the delivery of high quality, rapid results, is central to our mission of advancing health and healing to every patient we serve,” said Dr. Todd Johnson, CEO, Kashi Clinical Laboratories. “We’re proud to expand our collaboration with Thermo Fisher Transplant Diagnostics to deliver services for lung, in addition to kidney and heart transplant testing.”
For more information about MMDx™:
- Thermo Fisher Scientific MMDx™ Lung Press Release
- Kashi MMDx™ Testing Services
- Full MMDx™ Portfolio Information
MMDx and Molecular Microscope are trademarks of Transcriptome Sciences Inc.
MMDx Lung was developed and validated by Kashi Clinical Laboratories, LLC. This laboratory developed test (LDT) is used for clinical purposes by the CLIA-certified laboratory performing the test. This test has not been cleared or approved by the US FDA or CE marked in the EU as an in vitro diagnostic test.
About Kashi Clinical Laboratories
Kashi Clinical Laboratories (KCL) is a fully accredited clinical laboratory providing specialized solutions to academic institutions, biopharma, hospitals, long-term care facilities, and transplant centers around the world. Founded in 2006, KCL provides a full range of pre and post-transplant testing services, clinical pathology and genomics, virology, genetic testing, toxicology, and clinical trial support. KCL is known for its rapid turnaround time, scientific expertise, customer service, and innovation using state-of-the-art technology.
